INTRODUCTION
Radionuclide bone imaging is useful for detection of bone metastases from malignant neoplasms of many different origins. Breast carcinoma and prostate carcinoma are the most prevalent primary tumors that metastasize to bone at some point during their clinical course. On the contrary, other malignant neoplasms, lung, bladder, kidney, stomach, gastrointestinal, uterus and thyroid carcinomas, develop bone metastases more rarely. The incidence of bone metastases at postmortem examination in different cancers is shown in Table 1 (1). Tc-MDP is the most widely used agent to image bone metastases (6) .
BONE SEEKING AGENTS AND MECHANISMS OF UPTAKE
Bone metastases begin as medullary lesions. As the lesion enlarges, the surrounding cortical bone undergoes both osteoclastic and osteoblastic changes. Bone can be destroyed directly by the tumor cells or indirectly by specific mediators which stimulate reabsorption by osteoclasts (12) . Depending on the proportion of these clastic and blastic changes, the radiographic appearance will be lytic, blastic or mixed. On one hand, lytic lesions may be associated with a very rapidly growing metastasis so that an osteoblastic repair component is unable to keep pace, such as seen with metastases from lung or kidney carcinoma. Lesions with lytic appearance, however, may also be slowly growing so that an osteoblastic response is only minimally stimulated which is seen in metastases derived from myeloma or thyroid carcinoma. Alternately, tumors like myeloma may release a substance that inhibits the osteoblastic response. On the other hand, sclerotic lesions are seen in bone metastatic tumors with slower, but steady growth (e.g. prostate). Sclerotic lesions may actually be a sign of healing of a lytic process (13) . 
Bone: From planar imaging to SPECT & PET/CT

IMAGING OF BONE METASTASES Bone scintigraphy
Either direct visualization of tumor cells or secondary bone reaction to the malignant cells, establishes a basis for detection of malignant bone lesions. The mechanism of visualizing bone metastases is dependent on detection of the reactive (osteoblastic) response to invading tumor. In most of the cases, osteoblasts are stimulated in response to tumor and the new bone mineral formed accumulates the radiotracer 99m Tc-labeled phosphates/phosphonates; consequently producing "hot" spots on a bone scan. In a few cases, tumor may produce a predominantly lytic reaction producing a photopenic area. Radiopharmaceuticals, such as 99m Tc-MDP detect the osteoblastic response to invading tumor (14). Uptake of diphosphonates depends on local blood flow, osteoblastic activity and extraction efficiency. Most likely, the diphosphonates are incorporated into the hydroxyapatite crystal on the bone surface (6). There are two techniques for bone scintigraphy: either a whole-body scan versus multiple static scans of the entire body. In both cases, if there are some suspicious areas, additional spot views should be done. Regardless of the specific technique, radionuclide bone imaging is able to detect metastases much earlier than conventional plain film radiography (14). During the last decade, single photon emission tomography (SPECT) improved on planar imaging and is being used more and more (15) . SPECT is more sensitive than planar scintigraphy; SPECT imaging identifies disease seen on CT but missed on planar scintigraphy in onethird of patients (16) . This technique has an important role in patients with chronic low back pain (17) , facet syndrome (18), sacroiliitis (19) , avascular necrosis (20-23), diagnosis of meniscal tears (24) (25) (26) , etc. SPECT is useful in the assessment of metastatic disease because of its precise localization of vertebral involvement as well as greater sensitivity for the detection of vertebral metastases. Based on these features, it is able to improve the differentiation between malignant and benign lesions (27, 28) (Figure 1 and Figure 2 
Positron emission tomography
In recent years, with the availability of positron emission imaging (PET) imaging, the use of 18 F as the fluoride ion has increased. In general, PET imaging has better spatial resolution. The mechanism of 18 F -Fluoride is similar to that of 99m Tc-MDP and depends on regional blood flow and osteoblastic activity. It is selectively accumulated at sites of high bone turnover and remodeling by chemisorption onto bone surfaces, exchanging with hydroxyl (OH-) groups in hydroxyapatite crystal of bone resulting in forming of the fluoroapatite (29) . In general, 18 F -Fluoride will be the best for blastic lesions. 18 F-Fluoride PET takes advantage of the better pharmacokinetic characteristics of 18 F-Fluoride, and the better imaging characteristics of PET technology. Increased 18 F-Fluoride uptake may be detected in both sclerotic and lytic metastases. The minimal osteoblastic activity accompanying a lytic lesion, which may not be identified on 99m Tc-MDP bone scan may be readily identified with 18 F-Fluoride PET imaging. PET imaging with 18 F-fluoro-2-deoxyglucose ( 18 F-FDG) has also been evaluated as a tracer to identify bone metastases. 18 F-FDG is directly incorporated into the tumor cells and consequently detects cortical and marrow involvement. This suggests that this radiopharmaceutical will be best for lytic lesions. The fact that 18 F-FDG PET has low uptake in normal red marrow, allows for early detection of malignant bone marrow involvement preceding detection of bone metastases by bone scan using bone-specific radiotracers and computed tomography (CT). F-FDG PET imaging of predominantly osteoblastic lesions but it has higher overall sensitivity due to more frequent occurrence of osteolytic bone metastases (33) . The added values of FDG PET/CT are: better resolution provides localizing bone versus tissue lesions, differentiating benign from malignant sites of bone tracer uptake, providing additional help in identifying sites for biopsy, and enhancing radiotherapy treatment planning (34) . If compared to 99m Tc-MDP and 18 F-Fluoride, 18 F-FDG PET is more sensitive for detection of bone metastases secondary to lung cancer. In breast cancer bone metastases, 18 F-FDG appears to be more sensitive for lytic lesions, but less sensitive for sclerotic ones. Conversely, 18 F-FDG PET is less sensitive in detection of bone metastases from prostate cancer. Thus, post-treatment studies which often result in sclerotic lesions are negative with 18 F-FDG imaging because they have healed and no longer have viable tumor (6) (Figure 3 ).
CONCLUSION
Cortical bone tracers, 99m-Tc-MDP and fluoride (18F) (FNa) PET/CT, have a role in detection of sclerotic blastic lesions of metastatic disease. PET scan has better sensitivity over CT in detecting metastatic bone lesions. Fluorodeoxyglucose (18F) (FDG) PET/CT is more sensitive in detection of lytic lesions, while 18-F-fluoride is good for both, scletoric and lytic metastases. Most recently, a new radioisotope, fluorocholine(18F) (FCH) PET/CT, seems to be promising in detection of bone metastases in patients with prostate cancer. At present, fluorocholine is officially registered for the detection of bone metastases only, but most likely it will find a role in detection of local/locoregional node recurrence in near future. 
